)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Stereotaxis (STXS) investor relations material
Stereotaxis Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary11 Nov, 2025
Executive summary
Achieved FDA approval of Genesis X robotic system, launched MAGIC and MAGIC Sweep catheters, and completed the acquisition of Access Point Technologies EP, Inc. (APT), expanding product offerings and in-house catheter development.
Two new Genesis system orders from European hospitals, reflecting robust demand and expansion of new robotic programs in Europe.
Recurring revenue growth driven by new catheter launches, notably MAGIC Sweep in the U.S. and MAGIC ablation catheter in Europe, with MAGIC Sweep generating over $300,000 in its first two months.
Gross margin improved to 55% in Q3 2025 from 45% a year ago, mainly due to product mix.
Operating loss for Q3 2025 was $6.6 million, with net loss attributable to common stockholders of $6.5 million.
Financial highlights
Q3 2025 revenue was $7.5 million: $1.9 million from systems and $5.6 million from recurring revenue; nine-month revenue rose 15% to $23.7 million.
Gross margin was 55%; recurring revenue gross margin 67%, system gross margin 19%.
Operating loss and net loss were $6.6 million and $6.5 million; adjusted operating loss and net loss (excluding non-cash charges) were $2.5 million and $2.4 million.
Cash and equivalents at quarter-end were $10.5 million, with no debt; pro forma cash including pending financing would be $14.5 million.
$8.5 million raised in July 2025 direct offering; additional $4 million expected in Q4 2025.
Outlook and guidance
Q4 2025 revenue expected to exceed $9 million, with system revenue around $3 million and recurring revenue over $6 million.
Full-year 2025 revenue growth projected at over 20% year-over-year, with double-digit growth guidance reaffirmed.
2026 expected to see sustained growth in both system and recurring revenue, with quarterly revenue projected to average over $10 million.
Management expects continued losses in 2025 as investments in R&D, commercialization, and regulatory approvals persist.
Cash on hand, including proceeds from equity raises, is expected to fund operations, but additional financing may be needed if macroeconomic conditions worsen.
Catheter portfolio's future growth drivers
How will $10M quarterly revenue impact profitability?
What drives new Genesis system adoption?
GenesisX full launch timeline?
MAGiC US FDA approval status?
PFA collaboration next milestones?
Genesis X premium pricing & sales model impact
Magic PFA collaboration: What's its strategic value?
Synchrony: SaaS revenue stream long-term potential
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Stereotaxis earnings date
Q4 20255 Mar, 2026
Next Stereotaxis earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Stereotaxis designs, manufactures, and distributes robotic systems, instruments and information systems for the interventional laboratory in the United States, Canada and Europe. Stereotaxis products are sold to hospitals with interventional laboratories by a direct sales force. The company's remote magnetic navigation system provides a physician with computer-controlled robotic control of catheter positioning and ablation systems during minimally invasive procedures.
This year the company has introduced it's web based system for real-time data-analysis allowing doctors to predict arrhythmias up to 4 days before they happen. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage